Logo of jester cap with thought bubble.

Image source: The Motley Fool.

Accuray Inc (NASDAQ:ARAY)
Q1 2020 Earnings Call
Oct 29, 2019, 4:30 p.m. ET

Contents:

  • Prepared Remarks
  • Questions and Answers
  • Call Participants

Prepared Remarks:

Operator

Ladies and gentlemen, thank you for standing by and welcome to the Q1 Fiscal 2020 Accuray Incorporated Earnings Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions]

I would now like to introduce your host for your conference call, Mr. Doug Sherk, you may begin.

Doug Sherk -- Investor Relations

Thank you, Kevin, and good afternoon everyone. Welcome to Accuray's conference call to review financial results for the first quarter of fiscal year 2020, which ended September 30, 2019. In addition, during our call this afternoon, management will review recent corporate developments.

Joining us today are Joshua Levine, Accuray's President and Chief Executive Officer; and Shig Hamamatsu, Accuray's Senior Vice President and Chief Financial Officer.

Before we begin, I'd like to remind you that our call today includes forward-looking statements that involve risks and uncertainties, including statements regarding our fiscal 2020 guidance, including factors that could affect such guidance, expectations regarding market conditions in China, expectations related to new product shipments and future business plans and strategies. There are a number of factors that could cause actual results to differ materially from our expectations, including but not limited to risks associated with adoption of CyberKnife, TomoTherapy and Radixact Systems, operationalizing the China joint venture and over strategy in China. Timing of China user license issuances and tenders, the Company's ability to take advantage of the issuance of such licenses, future order growth, future revenue growth, profitability and macroeconomic factors outside of the Company's control.

These and other risks are more fully described in the news release we issued just after the market close this afternoon as well as in our filings with the Securities and Exchange Commission. The forward-looking statements on this call are based on information available to us as of today's date and we assume no obligation to update any forward-looking statements to reflect actual performance or results. Changes in assumptions or changes in other factors affect forward-looking information, except to the extent required by the applicable securities laws.

Two housekeeping items for today's call. First, during the Q&A session we request the participants to limit themselves to two questions and then requeue with any follow-ups. Second, all references we make the specific quarters in the prepared remarks are to our fiscal year quarters. For example, statements regarding our first quarter refer to our fiscal first quarter ended September 30th, 2019.

Now I'd like to turn the call over to Accuray's President and Chief Executive Officer, Josh Levine.

Joshua H. Levine -- President and Chief Executive Officer

Thank you, Doug. Good afternoon everyone and thank you for joining us on today's call.

Accuray's Q1 performance represented a reasonably solid start to our fiscal 2020. As we shared with you during our year-end earnings release in late August, we expected fiscal 2020 to be characterized by revenue growth primarily occurring in the second half of the year due to timing of China Type A licenses issuance and revenue recognition and we believe that projected timing is still valid.

First quarter gross orders exceeded our internal plan and revenue was in line with our plan for the quarter. Gross orders were $78.5 million representing a 28% growth over prior year first quarter. Order growth was primarily driven by our CyberKnife System, while Radixact maintained strong momentum representing over 60% of the total orders for the quarter.

Geographically in fiscal Q1, our EMEA and AMS regions were meaningful contributors to gross orders and we continue to see strong order growth from China, which contributed 11 new systems, 9 Type A and 2 Type B.

On the revenue side, revenue for the quarter was $89.6 million, which was in line with our internal plan expectations.

Turning to significant highlights, on October 9, the China National Health Commission announced the first round of Type A radiotherapy license awards for hospitals who had applications in the system for equipment. Of the 58 licenses that were awarded, 50 of them were for Accuray systems with TomoTherapy/Radixact Systems representing 60% of the awards and CyberKnife Systems, the remaining 40%. We need to remember that the process identified by the Ministry of Health requires a tender process following the license awards for all participating end user hospitals, prior to being able to take receipt of a Type A device. This tender process has been put in place to define the transactional terms and conditions related to each hospital's equipment order and will not initiate a competitive bidding situation that would result in changes in the specific device that the hospital has received the Type A licenses for.

We expect that based on the time-lines required for this tendering process, we would not begin to see revenue impact related to the China Type A awards until sometime in our fiscal fourth quarter and we remain excited about the China market opportunity as a significant growth catalyst for our business.

Turning now to our product development roadmap, we introduced our Synchrony motion compensation and correction technology on the Radixact platform at the Annual ASTRO meeting last month in Chicago and received strong customer interest over the course of the show for this exciting technology.

As we indicated last quarter, we have our primary clinical product evaluation site for Synchrony on Radixact, currently under way at Froedtert Hospital in Milwaukee. Over the course of the next two quarters, we expect to ramp up additional commercial reference sites that will help drive full scale commercialization going forward.

Another highlight at the ASTRO meeting was the presentation of an abstract from the PACE study that was subsequently published in the September 17, 2019 online issue of The Lancet Oncology journal. The PACE study is an international multi-center Phase III randomized controlled study that compares three different prostate cancer treatment regimens across multiple safety and effectiveness metrics. This is the first study that we are aware of that allows for a head-to-head comparative device data among both competitive products in the radiotherapy space and provides comparative data between radiotherapy and an alternative treatment modality, in this case robotically assisted prostatectomy.

The first on to reach target patient accrual and publish early toxicity results is referred to as the PACE-B arm of the study. The PACE-B trial is designed to determine whether ultra hyperfractionated SBRT offers therapeutic benefit over prostatectomy or conventionally fractionated or moderately hyperfractionated radiotherapy in the treatment of low and intermediate risk prostate cancer patients.

In this arm of the PACE study, patients are randomized to one of two treatment regimens, prostate SBRT treatment in five fractions utilizing Accuray's CyberKnife and conventional LINACs or IMRT treatment involving conventional fractionation or moderate hyperfractionation in 20 or 39 fractions utilizing conventional LINACs.

There are a total of 845 patients enrolled in the PACE-B arm of the study, 431 of which were treated with SBRT and 414 who were treated with IMRT. Of these subsets, 41% of the SBRT group was treated on CyberKnife and roughly 59% was treated on conventional LINACs. The results of the patient reported and clinician confirmed outcomes reported in the online September 17 issue of Lancet Oncology indicate two very important results.

First, that there was no difference in acute toxicity between the SBRT and control arms, indicating that patients can benefit from shorter treatment schedules without the risk of greater toxicity in the short-term.

The second result was that SBRT treatments on CyberKnife resulted in significantly fewer Grade 2 and higher acute urinary toxicity than treatments on conventional LINACs, 12.4% versus 30.6%, a 2.5 fold difference while maintaining equivalent levels of GI toxicity. CyberKnife's unique ability to deliver ultra hyperfractionated treatment allows patients to receive higher dose and shorter treatment regimens without the risk of greater toxicity or incidence of side effects.

Before I turn the call over to Shig, I'd like to welcome the newest member of our leadership team Suzanne Winter, who has joined us as Senior Vice President and Chief Commercial Officer. Suzanne comes to us from Medtronic, where she most recently served as Group Vice President for the Medtronic diabetes business, where she was responsible for annual revenues of $1.4 billion and over 2,000 employees.

Suzanne previously served as General Manager of GE Healthcare's Detection and Guidance Solutions business and has a strong and progressive track record of driving business growth across industry segments as diverse as radiology, neurology and general surgery. I'm excited about having Suzanne on-board and I'm confident she will become a key contributor to our future business growth.

And now I'd like to turn the call over to Shig.

Shig Hamamatsu -- Senior Vice President, Chief Financial Officer

Thank you, Josh. And good afternoon everyone. I will start with some detail on our gross order performance for the first quarter and then focus on certain highlights for the period. As Josh noted, gross orders for the first quarter were $78.5 million, up 28% over the prior year period. On a regional basis, orders in the Americas approximately doubled compared to the prior year with South America being the largest contributor.

And Japan and APAC each grew at a healthy double-digit rates over the prior year period. Within APAC, orders in China were $24 million compared to $11 million during the first quarter of last year. Orders in EMEA were a meaningful contributor to our Q1 gross orders but down compared to the prior year period due mostly to the customer timing.

From a product mix perspective, CyberKnife contributed approximately 40% of the total gross orders in Q1, which was an increase from 15% of gross orders in the first quarter last year. The TomoTherapy platform led by Radixact accounted for approximately 60% of the gross orders during the quarter.

Net age-outs for the quarter were $35.9 million consistent with the forecast we provided during our fiscal 2019 fourth quarter call. As we expected, more than 40% of this total came from China. We continue to believe that a meaningful number of the orders from China that aged out during the past two years will eventually convert to revenue.

The 50 Type A licenses recently awarded to hospitals for Accuray systems included several systems that were aged out of our backlog, as of September 30,, 2019. During the first quarter, we also recorded $3.6 million of cancellations and other adjustments. As a result, on a net basis, we generated $39 million of orders in the first quarter. We ended the first quarter with a backlog of $495 million, representing an increase of 7% from September 30, 2018.

Turning now to our income statement. Total revenue for the first quarter was $89.6 million, down from $95.8 million in the prior year. During our fiscal 2019 fourth quarter earnings call in August, we offered on an outlook for revenue during the first half of fiscal 2020 to be below fiscal 2019 levels and the 7% decline for the first quarter was in line with this expectation.

Our product revenue of $37.6 million during the quarter declined 9% compared to the prior year. Service revenue in the first quarter of was $52 million, down 4% from the prior year due to lower revenue from upgrades, purchases, service contracts, which as we discussed in prior calls can fluctuate from quarter-to-quarter.

From a product mix perspective, CyberKnife accounted for approximately 40% of the quarter's revenue, while the TomoTherapy platform accounted for the remaining 60%. Radixact' s revenue represented approximately 75% of the TomoTherapy revenue during the quarter.

Turning now the gross margin. Our product gross margin was 42.6%, up from 40.9% in the prior year period due to a higher mix of CyberKnife revenue. Service gross margin in the quarter was 32.5% compared to 38.5% in the prior year. There were two primary drivers of the lower-than-planned service margin for the quarter.

First, parts consumption was higher than normal, which we believe was an isolated incident related to specific high dollar parts.

Second, we experienced delays in the renewal of certain service contracts that we expect to execute in the near future. Overall, we expect to see service margin return to near historical levels for the remainder of this fiscal year, as we work through these items. Although our gross margin for the first quarter was 36.8% compared to 39.5% in the prior year.

Moving down the income statement. Operating expenses for the quarter were $37.2 million, a decrease of $5.4 million or 13% from the prior year. The prior year operating expenses of $42.6 million, included $3.7 million from a one-time accounts receivable impairment charge during the first quarter. Excluding the impact of this charge, operating expenses decreased by $1.7 million or 4% during the quarter.

We did not record any China joint venture loss pickup during the first quarter due to the timing of Accuray's contractual obligations related to our equity contribution. We expect to report our share of the JV loss starting in the third fiscal quarter.

Adjusted EBITDA was negative $1 million in the quarter compared to $4 million in prior-year period. The EBITDA decline was mainly the result of the year-over-year decline in revenue and commensurate decline on gross margin dollars during the quarter due to the lower service gross margin. We ended the first quarter with $87 million of cash and short-term restricted cash.

Turning now to our guidance for fiscal 2020. We are reiterating our guidance provided back in August with revenue expected to range between $410 million and $420 million. We continue to believe in our ability to return to revenue growth during the second half of this fiscal year, while we continue to expect our total first half revenue will be approximately 5% to 6% below fiscal 2019 levels.

Our revenue forecast for the full fiscal year, reiterated today does not include any incremental contribution from the 50 Type A licenses awarded in October, because the hospitals awarded the licenses still need to complete the tender process before a shipment date can be arranged.

Based on the time-lines required for this tendering process, we do not expect to see revenue impact related to China Type A awards until sometime in our fiscal fourth quarter. We are reaffirming our expectations for gross order growth in the mid-single-digit range during the fiscal 2020 with the Americas, EMEA and Japan regions leading the way.

During last year's second quarter, we received 16 orders from China as a government published the long-awaited quotas for Type A and B licenses in that quarter. While we expect solid gross orders from China during the second quarter, we do not believe we will match the 16 orders from the prior year period. Overall, our total second quarter gross orders are expected to be approximately $10 million to $13 [Phonetic] million below last year's level of $100 million.

We continue to expect adjusted EBITDA for the full-year to range between $19 million to $24 million, which includes approximately $2 million of our share of expected loss of the China joint venture operations. In terms of our gross margin outlook, we expect overall gross margin to be approximately flat to our fiscal 2019 levels of 39%. We expect operating expenses for fiscal 2020 to be down approximately 4% year-over-year as we see the benefit of the cost reduction actions that we took in the prior year.

Turning to our Q2 net age-out forecast, we anticipate Q2 net age-outs to be in the $18 million to $20 million range, which is approximately 50% less than the first quarter.

And with that, I'd like to hand the call back to Josh.

Joshua H. Levine -- President and Chief Executive Officer

Thank you, Shig. Operator, we're now ready to open the lines for questions.

Questions and Answers:

Operator

[Operator Instructions] Our first question comes from Josh Jennings with Cowen.

Bryan Bergin -- Cowen and Company -- Analyst

Bryan here for Josh. Thanks for taking my questions. With respect to being named in 50 out of the 58 Class A licenses, can you share how that compares to the level of participation you originally assumed?

Joshua H. Levine -- President and Chief Executive Officer

Our reference point for original assumptions really has to go back to where we were during the period of time, roughly 2.5 years or 3 years ago, when the government was still actually issuing licenses for Type A radiotherapy products. And if you go back to that stage we were operating at a place where we were -- we had a win rate of roughly low to mid '80s kind of wins across both platforms.

So this is very consistent with where we were in that prior period of time and we're pleased, very pleased with what ultimately now has become visible with regards to license award starting to flow. I think the other thing and just in addition to overall win rate, the fact that it's balanced across both platforms we think is another good indication of how important our products are to the more academically oriented medical centers and the larger public hospitals there in the local market.

Bryan Bergin -- Cowen and Company -- Analyst

Great, thank you. And with respect to the guidance, can you clarify what percentage of the total opportunity associated with these 50 Class A licenses that you expect to impact revenue in this fiscal fourth quarter?

Shig Hamamatsu -- Senior Vice President, Chief Financial Officer

Yes. This is Shig. I obviously can't be very specific about it, but I would characterize that as a modest amount of Type A revenue in the fourth quarter in that guidance number, based on awareness back in August when we provided the original guidance, how many license applications for our systems have been turned in.

We obviously had a great news of the 50 licenses won, which is really higher than what we had expected, but we have not really built-in any incremental units from that. Good news that we received into the guidance at this point because there are tender timing which is still uncertain that you heard about.

So what we want to do right now is we want to see the pace of that tender process play out before we make any revenue forecast or revision.

Bryan Bergin -- Cowen and Company -- Analyst

Okay, great. And then just last one on the tender process itself, just can you speak to Accuray's capacity to deal with multiple processes at once? Thank you for taking all my questions.

Joshua H. Levine -- President and Chief Executive Officer

When you're referring to multiple processes, I'm not sure that the tender process is -- the interaction there is basically between the end-user hospital and TomoKnife, our distributor, who you know as we've stated in prior discussions, we're basically involved in a transition kind of a format as they are winding down and the JV is winding up.

So the primary interactions for those -- the tender process will be TomoKnife directly with those end-user hospitals. But I think we stated on prior year-end call in August, we have inventory staged, we have a high degree of readiness relative to -- once the tender process is complete in a given hospital situation, once they're ready to take receipt, we have the ability to ship and be active at that -- hit the ground running, so to speak, right from the beginning.

Bryan Bergin -- Cowen and Company -- Analyst

Excellent, thanks for that.

Operator

Our next question comes from Anthony Petrone with Jefferies.

Anthony Petrone -- Jefferies -- Analyst

Thanks and congratulations on the traction in China. And maybe to start here with a few questions. Just on exactly how this process plays out. And so in terms of a license award, should we actually be looking at the license award as essentially a precursor to a booking? So is that a good way to look at it?

And then you mentioned last quarter, Josh, just in terms of Class B licenses, that's going to take a bit longer and part of that had to do with just the infrastructure that was in the process of essentially being put together to handle the tender process, if you can provide an update there, that would be helpful?

Joshua H. Levine -- President and Chief Executive Officer

Yes. So, Anthony, I think the answer on the Type B discussion is, essentially our Type B activity has been probably about 10% of the overall order activity that we've been generating in China. And again, as you've heard us talk about in the past, the primary focus for TomoKnife is they wind down the distribution relationship with us, it's really been on Type A.

The primary focus for the Type B products will be the distribution network that the JV has established and the product longer-term -- the product that's going to be built in Tianjin facility, that's now under construction with China Isotope and Radiation Corp.

So that the -- but again in the reported numbers for the quarter, there were 9 orders on Type A, they were 2 on Type B. But I think ultimately, we will start to see Type B start to ramp up more significantly as we get deeper into this. There were still -- if you go back to the number of orders or quotas that were established for Type A and Type B, you'll recognize that this is really just scratching the surface.

I mean the orders or the awards that had been identified in this first round of award or licenses in the first round of awards, basically were a third of the total Type A licenses that were identified in the quota. And on the Type B side, there was a total of almost 1,300 licenses identified for Type B product.

So we're really, really at early stages here, but we're pleased with where we're at in general. On the first part of your question.

Shig Hamamatsu -- Senior Vice President, Chief Financial Officer

Yes, Josh. I'm going to give a clarification. So the -- as to the 50 licenses awarded for end-users, a vast majority of that is represented by the orders we had already booked into our backlog, I would say as of June 30 last year. I mean -- excuse me, the past fiscal year. So, three, four months ago because you might recall that the 50 licenses issued were related to the applications turned in at the end of July, this past July. So, vast majority of that 50 relates to the orders we already had in our books, three, four months ago?

Anthony Petrone -- Jefferies -- Analyst

Okay, that's helpful. And then one quick follow-up if I may, just America orders nearly doubled. Obviously, there was concern on the CMS radiation oncology bundle, it doesn't look like at least from the reported results so far that there was any hiccup or impact to orders? So, any update on what you what Accuray is hearing around the RO bundle and the lack of impact in the quarter or what the expectations are in terms of implication for orders going forward? Thanks.

Joshua H. Levine -- President and Chief Executive Officer

Yes, Anthony, it's a great question. I think you'll remember the conversation we had in Chicago during the IR event at ASTRO and our view then and our view still today very consistently with what you heard from us already, is that we actually think that we are from a portfolio standpoint, very, very well-positioned to deal with the alternative payment model situation.

In general from a directional standpoint, we believe that what will happen over time is, you will see people that have been more predisposed to look at IMRT with greater number of fractions historically, they will be encouraged to move to SBRT related treatment probably using either moderately or ultra hyperfractionated treatment plans. And we think that favors our product portfolio, both platforms really strongly.

So we've seen no negative overhang, if you will, or no negative feedback at all from customers relative to the APM announcement and we're still bullish on longer-term on our positioning from a portfolio standpoint, related to that.

Anthony Petrone -- Jefferies -- Analyst

Thanks again. I'll get back in queue.

Operator

Our next question comes from Brooks O'Neil with Lake Street Capital Markets.

Brooks O'Neil -- Lake Street Capital Markets -- Analyst

Good afternoon, guys. I want to just zone in on China a little bit more. I have really two questions, obviously we've been talking about your disproportionate market share of Class A licenses so far for a number of years, but if you could just remind us why your competitive position is so strong in China right now.

And then obviously the next phase is going to be this tendering process and I'm curious if you could share and -- shed any light on whether the joint venture, you expect that to be a positive force in getting through the tendering process successfully or how do you view that right now?

Joshua H. Levine -- President and Chief Executive Officer

So, Brooks, the Type A discussion really goes back to the Company's roots or the early days of both product plots, both on the CyberKnife side and on the Tomo side, both platforms had been very distinctly focused on larger academic medical centers. There was a significant amount of work in the early days done in building relationships with key opinion leaders across both of the technologies.

If you remember some earlier conversations we've had, essentially we had in addition to academic medical centers with strong KOL endorsement, we had a very strong position in the PLA military hospital channel. And the reason for that was that the -- if you go back 10, 12 years ago, those hospitals were from a budgetary standpoint essentially they had open checkbooks, they had the best equipment, you could find and the best technologies you find across all the categories and they were rarely if ever constrained from a budgetary standpoint.

So you found a disproportionate number of the most important military hospitals and academic hospitals with both CyberKnife and TomoTherapy devices, really well represented in both of those customer profile types. We did some market research early on after I got to Accuray and one of the interesting things that we found was that, for a company of our size, given the market share we had, the brand awareness statistics and data from the market research that we did, said that the awareness, both at the -- on the clinical side of the world, but also in the -- in a more general sense population wise was disproportionate. Awareness of our products and the brands were disproportionate to our size relative to market share, which I thought was very interesting. And I think that that has continued to play itself out. When you think about where high ranking government officials in China, where they go, or where their families go for treatment they end up in PLA military channel hospitals or the end up in the large academic centers .

And so there is a high level of awareness across the MOH and the healthcare side of the government, from a public health policy standpoint, high level of awareness about our products to this very day that we think as an important kind of a foundational aspect or foundational advantage for us given our positioning. So, that I think is kind of the answer to the first part of your question.

Brooks O'Neil -- Lake Street Capital Markets -- Analyst

Yes.

Joshua H. Levine -- President and Chief Executive Officer

The second part is really around the tendering processes that you asked and the JV infrastructure will be assisting in some of the tender process, but I'm not believing that they're going to take the primary lead in it. I think that our existing distributor TomoKnife is -- because they have the relationships with the hospitals that have received the Type A licenses, they actually assisted those customers in application process, getting themselves in the queue for Type A licenses, they have the strongest relationship and working background with those accounts. And I think that as a consequence they are better positioned to support the efficient negotiation, if you will, or process management related to the tender.

And I know while it sounds like there is a lot, if you look at 50 different accounts, it sounds like a lot, but the bottom line is -- I don't think we've got a big concern that there were going to be challenges to that tendering process in terms of infrastructure support and focus. I mean the TomoKnife guys, as you might imagine, are a 110% focused on ensuring that those licenses get or the tenders get completed and so that they can put themselves in a first available position, if you will, to be able to receive a device.

Brooks O'Neil -- Lake Street Capital Markets -- Analyst

That's great. That sounds like there is a high probability, you can get those things across the goal line, which is fantastic.

Joshua H. Levine -- President and Chief Executive Officer

Yes, I would agree with that assessment.

Brooks O'Neil -- Lake Street Capital Markets -- Analyst

Thank you very much again.

Operator

[Operator Instructions] Our next question comes from Tycho Peterson with JP Morgan.

Elaine Wu -- JP Morgan -- Analyst

Hi, thanks. This is Elaine on for Tycho. Going back to your questions on China, can you maybe just talk about why your expectations on the time-line for the tendering process had changed with revenue recognition now pushed out to your fiscal fourth quarter and then what is the initial pacing and cadence, we should expect given the pent-up demand and how rapidly could you respond, once the tendering process concludes?

Joshua H. Levine -- President and Chief Executive Officer

So Elaine I would -- let me just kind of start by saying, I don't think our expectations or our view of the timing related to revenue impact in this discussion, I don't think they change really at all. I think if you go back to our prepared remarks and some of what you heard from us in Q&A over the last couple of quarters. The one thing we've been pretty consistent about is that every time we've tried to make grand predictions about timing related to China, we've been wrong, we've been disappointed. And so if anything we've taken a stance that says we're -- and I think it's been consistent over the last several quarters, we're going to take the long view on this, we're going to be conservative about it. And if things happen in a more rapid fashion, that's terrific, there's upside there. But -- so if you go back to again remarks from the prior earnings call, we said that we expected the -- between the timing of the license awards announcement and the tendering process, we were expecting that there was going to be impact, revenue impact late in our fiscal year. It was difficult to predict or near impossible to predict with any precision how much revenue impact and that's -- this is still kind of where we're at this point.

The good news is we have today, prior to the end of the calendar year, we've got license awards, let's say, that we've been a disproportionate winner, if you will, in the selection in Type A equipment. That's the good news. The challenge is that we still have some activities process wise that have to be worked through, the tendering piece specifically.

Again, I don't -- we don't have any information or any belief at this point that we will not -- that we won't get through that process, reasonably quickly. But for us to say that we've got a defined view about down to the day or down to the week, when that process will be complete, I'm just not prepared to put our credibility on the line at this point, again, and I think it's just best for us to say that we don't see any obstacles to getting the tendering process complete. We believe that we will start to have some revenue impact sometime during our fiscal fourth quarter. If tendering goes faster than we would imagine, then I would say the degree of revenue impact that could take place would be higher. It's just a matter of -- just sort of as a reminder, our current China backlog in round numbers is 59 units. So, in round numbers about 60 devices or about $130 million in backlog. About $115 million is Type A, about $16 million is Type B. So there's a lot to work within that backlog once tendering is complete and those accounts, those end-user hospitals are who are earliest in the queue are ready to take receipt of a device.

As I mentioned in the last call, we've got inventory built, we've got inventory staged and our ability to respond to the final completion of tendering and people ready to schedule installation and take delivery of equipment, our ability to support that is imminent. We're ready quite frankly now. So I think that's how I'd characterize it.

Elaine Wu -- JP Morgan -- Analyst

Okay, thanks. And then can you talk about the give and take on guidance, I believe you previously included some assumption for tariffs on 150 basis points top-line headwind and then also 150 basis points gross margin headwinds. So just wondering how you're assuming, given the tariff exemption?

Joshua H. Levine -- President and Chief Executive Officer

So we had a discussion and some review internally on this topic Elaine and we basically -- we put a press release out I think in early to mid-September, you'll probably remember that we said that we expect to benefit from the tariff exemption, that has not changed. We do expect it to benefit from the tariff exemption. But we are waiting for final clarification from the Chinese government on our exemption status.

I think we've got a very high degree of confidence on the Tomo, Radixact products. I think, again, because the CyberKnife is a little bit different animal than a conventional LINAC, we wanted to make sure that we had confirmation, full confirmation, from the government that the CyberKnife has -- will achieve the same level of exemption status that we're expecting on the Tomo, Radixact products.

And until we have that that clarification in hand, we think it's premature to change the guidance situation. Your estimate though of about 150 basis points is in the zipcode range of what that that benefit should be once we have clarification .

Elaine Wu -- JP Morgan -- Analyst

Okay. Great. Thank you.

Operator

And I'm not showing any further questions at this time, I'd like to turn the call back over to Josh Levine.

Joshua H. Levine -- President and Chief Executive Officer

Okay. I just want to thank everybody for participating today. We look forward to speaking with again in January when we attend the JP Morgan Annual Healthcare Conference and report our fiscal 2020 second quarter results later in that month. Thanks very much for your participation.

Operator

[Operator Closing Remarks]

Duration: 40 minutes

Call participants:

Doug Sherk -- Investor Relations

Joshua H. Levine -- President and Chief Executive Officer

Shig Hamamatsu -- Senior Vice President, Chief Financial Officer

Bryan Bergin -- Cowen and Company -- Analyst

Anthony Petrone -- Jefferies -- Analyst

Brooks O'Neil -- Lake Street Capital Markets -- Analyst

Elaine Wu -- JP Morgan -- Analyst

More ARAY analysis

All earnings call transcripts

AlphaStreet Logo